In conclusion, our preclinical data in mouse models support the development of pharmacological approaches to target BMI1-mediated mitochondrial regulation and protection from DNA damage as a novel therapeutic approach to stimulate endogenous, but possibly also transplanted, satellite cell self-renewal to sustain and enhance their contribution to muscle regeneration in DMD patients. The gene discussed is BMI1; the disease is Duchenne muscular dystrophy.